Moderna's mRNA-1403 Fails Early-Success Bar in Phase 3 Interim Look
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna said the Phase 3 interim analysis of mRNA-1403 did not meet the statistical criteria for early success, and it will not start an additional cohort this season. That is a setback for one of the pipeline programs the company has been counting on beyond its COVID franchise. It lands the same morning as the Q3 report showing 38 cents of EPS and a swing to profit, so the market has to weigh a clinical miss against an improving bottom line. The company gave no timeline for the next data readout on this program.
At the time of this announcement, MRNA was trading at $237.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.4B. The 52-week trading range was $22.28 to $261.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.